Felix W. Frueh
Research Subjects
Felix W. Frueh has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Henry T. Greely
Stanford University , 559 Nathan Abbott Way, Stanford, CA 94305
1 shared publication Lawrence J Lesko
US Food and Drug Administration, Office of Clinical Pharmacology, Silver Spring, MD, USA
1 shared publicationRichard D Hockett
Eli Lilly and Company, Indianapolis, IN, USA
1 shared publication- Robert C. Green
Division of Genetics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
1 shared publication Ronald A Salerno
Biologics Consulting Group Inc., Alexandria, VA, USA
1 shared publication- Stuart Hogarth
Department of Sociology, University of Cambridge, Cambridge, UK
1 shared publication
Latest Publications
- 29 February 2012
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 18 (4) , 201-205
On rat poison and human medicines: personalizing warfarin therapy
- 29 February 2012
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 18 (4) , 201-205
On rat poison and human medicines: personalizing warfarin therapy
- 1 October 2011
- Published by Elsevier in Drug Discovery Today
- Vol. 16 (19-20) , 898-901
Considerations for safety pharmacogenetics in clinical practice
- 1 October 2011
- Published by Elsevier in Drug Discovery Today
- Vol. 16 (19-20) , 898-901
Considerations for safety pharmacogenetics in clinical practice
- 1 June 2011
- Published by Springer Nature in Nature Reviews Genetics
- Vol. 12 (7) , 511-515
The future of direct-to-consumer clinical genetic tests
In light of the meeting of the US Food and Drug Administration (FDA) in March 2011 to discuss the regulation of clinical direct-to-consumer (DTC) genetic tests, we have invited five experts to consider the best means of overseeing the ordering and interpretation of these tests. Should these tests be regulated? If so, who, if anyone, should communicate results to consumers?
- 1 June 2011
- Published by Springer Nature in Nature Reviews Genetics
- Vol. 12 (7) , 511-515
The future of direct-to-consumer clinical genetic tests
In light of the meeting of the US Food and Drug Administration (FDA) in March 2011 to discuss the regulation of clinical direct-to-consumer (DTC) genetic tests, we have invited five experts to consider the best means of overseeing the ordering and interpretation of these tests. Should these tests be regulated? If so, who, if anyone, should communicate results to consumers?
- 23 April 2010
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 11 (5) , 657-660
Real-world Clinical Effectiveness, Regulatory Transparency and Payer Coverage: Three Ingredients for Translating Pharmacogenomics into Clinical Practice
The past decade of pharmacogenomics was driven by the sequencing of the human genome to create ever denser maps of genetic variations for studying the diversity across individuals. Today, genotyping technology is available at a fraction of the cost of what it was 10 years ago and many pharmacogenomic variations have been studied in detail. Still, we are only starting to gain an understanding of how pharmacogenomic-guided drug therapy affects clinical outcomes: real-world studies that demonstrate the clinical effectiveness and address the economic implications of pharmacogenomics are needed to help decide when and how to implement pharmacogenomics in clinical practice, how to regulate pharmacogenomic testing and how the healthcare system will integrate this new science into an environment of rapidly increasing cost.
- 23 April 2010
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 11 (5) , 657-660
Real-world Clinical Effectiveness, Regulatory Transparency and Payer Coverage: Three Ingredients for Translating Pharmacogenomics into Clinical Practice
The past decade of pharmacogenomics was driven by the sequencing of the human genome to create ever denser maps of genetic variations for studying the diversity across individuals. Today, genotyping technology is available at a fraction of the cost of what it was 10 years ago and many pharmacogenomic variations have been studied in detail. Still, we are only starting to gain an understanding of how pharmacogenomic-guided drug therapy affects clinical outcomes: real-world studies that demonstrate the clinical effectiveness and address the economic implications of pharmacogenomics are needed to help decide when and how to implement pharmacogenomics in clinical practice, how to regulate pharmacogenomic testing and how the healthcare system will integrate this new science into an environment of rapidly increasing cost.
- 20 July 2009
- Published by Taylor & Francis in Personalized Medicine
- Vol. 6 (4) , 377-380
Interview: Felix Frueh, Head of Personalized Medicine Research and Development at Medco
Felix W Frueh, PhD, is a Vice President of Medco Health Solutions (NJ, USA) where he leads Medco's personalized medicine research and development organization. In this function, Dr Frueh manages Medco's expanding research efforts in personalized medicine, leveraging the newest developments in science to improve the safety and effectiveness of prescription drug care. He is also responsible for the development of Medco's Personalized Medicine Research Center which is under construction in Whitestown (IN, USA). Prior to joining Medco, Dr Frueh was an Associate Director for Genomics at the US FDA, where he built up and led the core genomics review team in the Center for Drug Evaluation and Research, and chaired the first FDA-wide, interdisciplinary pharmacogenomics review group. Prior to the FDA, he was a managing partner at Stepoutside Consulting, LLC (MD, USA) and held senior positions at Transgenomic (NE, USA) and Protogene Laboratories (CA, USA). Dr Frueh's academic career includes a faculty appointment at the Departments of Pharmacology and Medicine at Georgetown University in Washington DC, USA, and postdoctoral fellowships at Stanford University (CA, USA) as well as the University of Basel, Switzerland, where he also received his PhD in biochemistry. Dr Frueh lives in Maryland, USA, with his wife and two sons.
- 20 July 2009
- Published by Taylor & Francis in Personalized Medicine
- Vol. 6 (4) , 377-380
Interview: Felix Frueh, Head of Personalized Medicine Research and Development at Medco
Felix W Frueh, PhD, is a Vice President of Medco Health Solutions (NJ, USA) where he leads Medco's personalized medicine research and development organization. In this function, Dr Frueh manages Medco's expanding research efforts in personalized medicine, leveraging the newest developments in science to improve the safety and effectiveness of prescription drug care. He is also responsible for the development of Medco's Personalized Medicine Research Center which is under construction in Whitestown (IN, USA). Prior to joining Medco, Dr Frueh was an Associate Director for Genomics at the US FDA, where he built up and led the core genomics review team in the Center for Drug Evaluation and Research, and chaired the first FDA-wide, interdisciplinary pharmacogenomics review group. Prior to the FDA, he was a managing partner at Stepoutside Consulting, LLC (MD, USA) and held senior positions at Transgenomic (NE, USA) and Protogene Laboratories (CA, USA). Dr Frueh's academic career includes a faculty appointment at the Departments of Pharmacology and Medicine at Georgetown University in Washington DC, USA, and postdoctoral fellowships at Stanford University (CA, USA) as well as the University of Basel, Switzerland, where he also received his PhD in biochemistry. Dr Frueh lives in Maryland, USA, with his wife and two sons.
- 15 July 2009
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 10 (7) , 1077-1081
Back to the Future: Why Randomized Controlled Trials Cannot be the Answer to Pharmacogenomics and Personalized Medicine
Randomized controlled trials are the gold standard for determining the efficacy of therapeutic interventions. However, medical practice has not evolved around the concept of randomized trials, but around the idea of careful observations, (anecdotal) case studies and the evaluation of retrospective data. Interventions discovered by these means and taken forward into clinical practice became standard practice as they continued to be superior when compared with prior or alternative types of treatment. Personalized medicine refers to an approach of clinical practice where a particular treatment is not chosen based on the 'average patient', but on characteristics of an individual patient, for example, a genetic profile that may vary from one patient to another, and therefore, allows to 'personalize' the treatment to a patient's individual needs. While the call for prospective randomized controlled trials to assess the effective use of such measurement may make sense in some cases, it is, when applied without distinction, hindering the implementation of personalized medicine. Important evidence for the validity and clinical effectiveness of using biomarkers, for example, a patient's genetic profile, can be gained from alternative approaches, including case-control and cohort studies, and retrospective analyses of data. Hence, we need to re-focus on approaches that are neither new nor unproven, but have been ignored over the last few decades.
- 15 July 2009
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 10 (7) , 1077-1081
Back to the Future: Why Randomized Controlled Trials Cannot be the Answer to Pharmacogenomics and Personalized Medicine
Randomized controlled trials are the gold standard for determining the efficacy of therapeutic interventions. However, medical practice has not evolved around the concept of randomized trials, but around the idea of careful observations, (anecdotal) case studies and the evaluation of retrospective data. Interventions discovered by these means and taken forward into clinical practice became standard practice as they continued to be superior when compared with prior or alternative types of treatment. Personalized medicine refers to an approach of clinical practice where a particular treatment is not chosen based on the 'average patient', but on characteristics of an individual patient, for example, a genetic profile that may vary from one patient to another, and therefore, allows to 'personalize' the treatment to a patient's individual needs. While the call for prospective randomized controlled trials to assess the effective use of such measurement may make sense in some cases, it is, when applied without distinction, hindering the implementation of personalized medicine. Important evidence for the validity and clinical effectiveness of using biomarkers, for example, a patient's genetic profile, can be gained from alternative approaches, including case-control and cohort studies, and retrospective analyses of data. Hence, we need to re-focus on approaches that are neither new nor unproven, but have been ignored over the last few decades.
- 23 December 2008
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 10 (1) , 111-115
4th US FDA–Drug Information Association Pharmacogenomics Workshop, Held 10–12 December, 2007
The 4th US FDA/Industry workshop, in a series on Pharmacogenomics, was on 'Biomarkers and Pharmacogenomics in Drug Development and Regulatory Decision Making' and was held on December 10-12, 2007 in Bethesda, MD, USA, with clear objectives to continue the dialogue that began in 2002 for enabling the use of biomarkers and pharmacogenomics in drug development and regulatory decision-making. This brief commentary will highlight the major topics and outcomes discussed at this meeting that was jointly sponsored by the FDA, The Pharmacogenomics Working Group (PWG), The Pharmaceutical Research and Manufacturers of America (PhRMA), The Biotechnology Industry Organization (BIO) and The Drug Information Association (DIA).
- 23 December 2008
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 10 (1) , 111-115
4th US FDA–Drug Information Association Pharmacogenomics Workshop, Held 10–12 December, 2007
The 4th US FDA/Industry workshop, in a series on Pharmacogenomics, was on 'Biomarkers and Pharmacogenomics in Drug Development and Regulatory Decision Making' and was held on December 10-12, 2007 in Bethesda, MD, USA, with clear objectives to continue the dialogue that began in 2002 for enabling the use of biomarkers and pharmacogenomics in drug development and regulatory decision-making. This brief commentary will highlight the major topics and outcomes discussed at this meeting that was jointly sponsored by the FDA, The Pharmacogenomics Working Group (PWG), The Pharmaceutical Research and Manufacturers of America (PhRMA), The Biotechnology Industry Organization (BIO) and The Drug Information Association (DIA).